Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472811 | 0.84 | SHBG (0.37) | SHBGCYP3A4SMN1; SMN2USP2MEN1 | |
| SCHEMBL29140765 | 0.78 | CYP2C19 (0.32) | CYP2C19LMNA | |
| SCHEMBL152840 | 0.76 | CYP2C19 (0.51) | SMN1; SMN2KMT2ACYP2C19KDM4EHIF1A | |
| SCHEMBL5688961 | 0.73 | KDM4E (0.40) | SMN1; SMN2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL28165578 | 0.71 | ALDH1A1 (0.34) | SHBGCYP3A4SMN1; SMN2USP2MEN1 | |
| SCHEMBL9070169 | 0.71 | SHBG (0.50) | SHBGCYP3A4SMN1; SMN2USP2MEN1 | |
| SCHEMBL1269005 | 0.71 | CYP3A4 (0.33) | SHBGCYP3A4SMN1; SMN2USP2MEN1 | |
| SCHEMBL9247513 | 0.68 | AKR1C2 (0.51) | SHBGCYP3A4SMN1; SMN2USP2MEN1 | |
| SCHEMBL10882790 | 0.65 | ABCB11 (0.40) | CYP3A4SMN1; SMN2MEN1TP53MAPT | |
| SCHEMBL10947681 | 0.65 | CYP3A4 (0.54) | SHBGCYP3A4SMN1; SMN2USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734976-A2 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RyCarma Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025006617-A2 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240376133-A9 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-11-14 | — | — | US | disclosed |
| EP-3257887-B1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | SAUDI ARAMCO TECH CO (SA) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4381070-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | Phio Pharmaceuticals Corp. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4323340-A2 | E3 LIGASE BINDERS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11878019-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230416283-A1 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-28 | — | — | US | disclosed |
| EP-2917203-A1 | PYRROL-1 -YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014071247-A1 | PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20120158026-A1 | GASTROINTESTINAL IMPLANT DEVICE | VYSERA BIOMEDICAL LIMITED (IE) | 2012-06-21 | — | — | US | disclosed |
| EP-2370436-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | Link Medicine Corporation (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010057006-A9 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010057006-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20060166278-A1 | Method for synthesizing sugar chain(s) | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1640379-A1 | METHOD OF SYNTHESIZING SUGAR CHAIN | Mitsubishi Chemical Corporation (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-0938475-A1 | PIPERIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998017647-A1 | PIPERIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376133-A9 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | PGD, CDCA2, MCM2 | SHBG 4265/4885CYP3A4 269/4885SMN1; SMN2 456/4885 |
| US-11878019-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | SIK2, SIK1, SIK3 | SHBG 4579/4885CYP3A4 3080/4885SMN1; SMN2 3859/4885 |
| US-20230416283-A1 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | PGD, CDCA2, MCM2 | SHBG 4265/4885CYP3A4 269/4885SMN1; SMN2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.